Date: 2011-02-18
Type of information: Licensing agreement
Compound: Traumakine-program including FP-1201
Company: Faron Pharmaceuticals (Finland) Maruishi Pharmaceutical (Japan)
Therapeutic area: Cardiovascular diseases
Type agreement: licensing
development
commercialisation
Action mechanism:
Disease:
Details: Faron Pharmaceuticals and Maruishi Pharmaceutical have signed a license agreement which grants Maruishi the exclusive license for the development and commercialization of the Traumakine-program in Japan. This agreement is subsequent to the Letter of Intent which was concluded on December 28th 2010. Faron’s leading drug candidate FP-1201 is the main target of this collaboration and is currently in phase II in the UK. The trial FPCLI001 recruits for the second part of the study and will use the selected optimal tolerated dose to treat patients who suffer from vascular leakage. With eight centers in the UK now actively enrolling, Faron expects the recruitment and biomarker analysis to be completed during H1-2011. In addition to safety and tolerability, the second phase of the study will also assess the preliminary efficacy of FP-1201 anddetermine the sensitivity of CD73 to act as a biomarker for treatment effect.The companies have started to initiate planning of Traumakine’s clinical program and preparation of the orphan drug application in Japan.
Financial terms: Financial details were not disclosed.
Latest news:
